Nav: Home

Advances prompt release of new recommendations for diagnosis, management of adult AML

January 25, 2017

Columbus, Ohio - An international panel of experts has released updated evidence-based and expert-opinion-based recommendations for the diagnosis and treatment of acute myeloid leukemia (AML) in adults.

The recommendations were issued by the European LeukemiaNet (ELN) and published in the journal Blood. The paper's senior author was Clara D. Bloomfield, MD, Distinguished University Professor, Ohio State University Cancer Scholar and Senior Adviser, and the William Greenville Pace III Endowed Chair in Cancer Research.

"These guidelines are an important update of the current and widely used recommendations for managing AML, for constructing clinical trials and for predicting outcomes of AML patients," says Bloomfield, who co-chaired the panel. "They will be the new standard of care and will replace the 2010 ELN recommendations for managing AML patients and designing clinical trials."

Adult AML affects an estimated 21,400 Americans per year and kills 10,600 of them, according to the American Cancer Society.

The updated recommendations include revised ELN genetic categories, a proposed response category based on minimal residual disease status, and a proposed category for progressive disease for clinical trials. They also include the newly updated World Health Organization classification of myeloid neoplasms and acute leukemia, also published in the journal Blood.

Bloomfield said updating the ELN recommendations was prompted by new insights into the molecular and genomic causes of the disease, by the development of new genetic tests and tests for detecting minimal residual disease and by the development of novel anti-leukemic agents.

The panel that produced the new guidelines included 22 international members with recognized AML clinical and research expertise. Bloomfield notes three particularly significant changes in the updated ELN recommendations:
  • There are now three genetic-risk categories, rather than four, and the FLT3-ITD mutation has been added as a marker of risk;

  • "Complete remission with no evidence of minimal residual disease" is a new proposed response category; this criterion requires that genetic markers present at diagnosis are no longer detectable. "It is no longer good enough to examine bone-marrow samples and say the leukemia is gone," Bloomfield says. "We must also see the loss of genetic markers."

  • "Progressive disease" is a new provisional response category to be used in clinical trials only; the purpose of the category is to harmonize the various definitions of progressive disease that are used in different clinical trials.
-end-
Funding from the Deutsche Forschungsgemeinschaft, the U.S. National Cancer Institute (grants CA180861, CA016058 ) and grants from multiple other countries supported this research.

Other researchers involved in this study were Hartmut Döhner, University of Ulm, Ulm, Germany; Elihu Estey and Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center; David Grimwade, King's College London, UK; Sergio Amadori and Francesco Lo-Coco, Università di Roma "Tor Vergata," Rome, Italy; Thomas Büchner, University of Münster, Münster, Germany; Hervé Dombret, Assistance Publique-Hôpitaux de Paris, Paris, France; Benjamin L. Ebert, Brigham and Women's Hospital, Harvard Medical School; Pierre Fenaux, Hôpital Saint Louis, Paris, France; Richard A. Larson, University of Chicago; Ross L. Levine and Martin S. Tallman, Memorial Sloan Kettering Cancer Center; Tomoki Naoe, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Dietger Niederwieser, University of Leipzig, Leipzig, Germany; Gert J. Ossenkoppele, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; Miguel Sanz, University of Valencia, Valencia, Spain; Jorge Sierra, Autonomus University of Barcelona, Spain; Hwei-Fang Tien, National Taiwan University Hospital, Taipei, Taiwan; Andrew H. Wei, The Alfred Hospital and Monash University, Melbourne, Australia; and Bob Löwenberg, Erasmus University Medical Center, Rotterdam, The Netherlands.

About the OSUCCC - James

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 47 National Cancer Institute-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program's 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.

Ohio State University Wexner Medical Center

Related Leukemia Articles:

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.
Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.
Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.
Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.
The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.
Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.
Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.
Finding second hits to knock out leukemia
Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks.
Understanding the emergence of leukemia
Acute T-cell lymphoblastic leukemia is a rare type of blood cancer that affects mostly children.
More Leukemia News and Leukemia Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Meditations on Loneliness
Original broadcast date: April 24, 2020. We're a social species now living in isolation. But loneliness was a problem well before this era of social distancing. This hour, TED speakers explore how we can live and make peace with loneliness. Guests on the show include author and illustrator Jonny Sun, psychologist Susan Pinker, architect Grace Kim, and writer Suleika Jaouad.
Now Playing: Science for the People

#565 The Great Wide Indoors
We're all spending a bit more time indoors this summer than we probably figured. But did you ever stop to think about why the places we live and work as designed the way they are? And how they could be designed better? We're talking with Emily Anthes about her new book "The Great Indoors: The Surprising Science of how Buildings Shape our Behavior, Health and Happiness".
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.